Binimetinib and Nivolumab for the Treatment of Locally Advanced Unresectable or Metastatic BRAF V600 Wildtype Melanoma

  • End date
    Jun 1, 2024
  • participants needed
  • sponsor
    Jonsson Comprehensive Cancer Center
Updated on 28 May 2022


This phase II trial studies how well binimetinib and nivolumab work in treating patients with BRAF V600 wildtype melanoma that has spread to nearby tissues or lymph nodes and cannot be removed by surgery (locally advanced unresectable) or has spread to other places in the body (metastatic). Binimetinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving binimetinib and nivolumab together may work better in treating patients with melanoma compared to nivolumab alone.



I. Objective response rate (ORR), which is defined as the proportion of response-evaluable participants either with a confirmed complete response (CR) or partial response (PR) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1, as determined by the investigator assessment, at best overall response.


I. Progression-free survival (PFS), clinical benefit rate (CR + PR + stable disease [SD] among response-evaluable participants, per RECIST 1.1), overall survival (OS) and duration of response (DOR).


I. Evaluation of histologic evidence of response (p-ERK reduction in residual tumor cells and CD8 T cell or tumor infiltrating lymphocytes or tumor infiltrating lymphocyte [TIL] infiltration induced by combination treatment) using pretreatment and early on-treatment tumor biopsies.


Patients receive binimetinib orally (PO) twice daily (BID) on days 1-28 and nivolumab intravenously (IV) over 30 minutes on day 1. Treatment repeats every 4 weeks for up to 12 cycles in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up every 3 months for up to 1 year, then annually thereafter.

Condition Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Locally Advanced Cutaneous Melanoma, Metastatic Cutaneous Melanoma, Pathologic Stage III Cutaneous Melanoma AJCC v8, Pathologic Stage IIIA Cutaneous Melanoma AJCC v8, Pathologic Stage IIIB Cutaneous Melanoma AJCC v8, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IIID Cutaneous Melanoma AJCC v8, Pathologic Stage IV Cutaneous Melanoma AJCC v8, Unresectable Cutaneous Melanoma
Treatment questionnaire administration, Nivolumab, Binimetinib
Clinical Study IdentifierNCT04375527
SponsorJonsson Comprehensive Cancer Center
Last Modified on28 May 2022


Yes No Not Sure

Inclusion Criteria

Males or females age >= 18 years
Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-1
Histologically confirmed locally advanced/unresectable or metastatic cutaneous melanoma
Measurable disease per RECIST version (v.) 1.1 criteria using imaging scans, OR peripheral lesions that can be adequately documented with a picture and a ruler even if they do not meet RECIST criteria
Patient must have failed prior alphaPD-1 or alphaPD-1 + alphaCTLA-4 therapy in the metastatic setting
V600BRAF wildtype tumor status confirmed by Clinical Laboratory Improvement Act (CLIA) approved lab
Hemoglobin >= 8.0 g/dL
Whole blood cell count (WBC) >= 2,000/mm^3
Absolute neutrophil count >= 1,500/mm^3
Platelet count >= 75,000/mm^3
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3.0 x institutional upper limit of normal (ULN), (=< 5.0 x ULN in those with hepatic metastases)
Bilirubin =< 1.5 x ULN; for subjects with documented/suspected Gilbert's disease, bilirubin =< 3 x ULN
Albumin >= 2.5 g/dl
Serum creatinine =< 2.0 x upper limit of normal (ULN)
Left ventricular ejection fraction (LVEF) >= 50% assessed by echocardiogram (ECHO) or multiple-gated acquisition (MUGA) scan completed =< 180 days (6 months) before initiation of protocol treatment
Patients must be willing to submit blood and tissue specimens for translational medicine studies
Patients must have a site of disease amenable to biopsy and be a candidate for biopsy
Women of childbearing potential (WOCBP) must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of human chorionic gonadotropin [HCG]) at screening and within 24 hours prior to the start of study drug
Women of childbearing potential (WOCBP) must be willing to use either two adequate barrier methods or a barrier method plus a hormonal method of contraception to prevent pregnancy, or to abstain from heterosexual activity (complete abstinence) throughout the study, starting with visit 1 through 5 months after the last dose of study therapy. Approved contraceptive methods include, for example, intrauterine device, diaphragm with spermicide, cervical cap with spermicide, male condoms, female condoms with spermicide, or oral contraceptives. Spermicides alone are not an acceptable method of contraception. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately
Male patients must agree to use an adequate method of contraception, or to abstain from heterosexual activity (complete abstinence) starting with the first dose of study drug through 5 months after the last dose of study therapy

Exclusion Criteria

Contraindications to tumor biopsy (coagulopathy, known history of keloid formation, etc.)
Women who are pregnant or breastfeeding
Prior therapy with a MEK inhibitor (e.g., binimetinib, trametinib, cobimetinib)
Known hypersensitivity or contraindication to any component of binimetinib or its excipients
Inability to swallow and retain study drug
Patients who have received prior lines of systemic therapy in the advanced/metastatic setting (not including, neoadjuvant, adjuvant, or maintenance therapy)
Received anticancer therapy including chemotherapy, immunotherapy, or antineoplastic biologic therapy (e.g., erlotinib, cetuximab, bevacizumab etc.), within 14 days prior to start of study treatment or exposure to any investigational drug within 7 days prior to screening visit or for which 5 half-lives have not elapsed
Participants who have undergone major surgery (e.g., in-patient procedures) =< 6 weeks prior to start of study treatment or who have not recovered from side effects of such procedure
Participants who have had radiotherapy =< 14 days prior to start of study treatment or who have not recovered from side effects of such procedure. Note: Palliative radiation therapy must be complete 7 days prior to the first dose of study treatment
Participants who have not recovered to =< grade 1 from toxic effects of prior therapy before starting study treatment
Note: Stable chronic conditions (=< grade 2) that are not expected to resolve (such as neuropathy, myalgia, alopecia, prior therapy-related endocrinopathies) are exceptions and may enroll
Uncontrolled or symptomatic brain metastases or leptomeningeal carcinomatosis that are
Subjects with active, known, or suspected autoimmune disease. Subjects with type I diabetes mellitus, hypothyroidism only requiring hormone replacement, skin disorders (such as vitiligo, psoriasis or alopecia) not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger are permitted to enroll
not stable, require steroids, are potentially life-threatening or have
Uncontrolled or significant cardiovascular disease including, but not limited to, any of the following
required radiation within 28 days prior to starting study drug. Note: Patients
Myocardial infarction (MI) or stroke/transient ischemic attack (TIA) within the 6 months prior to consent
with previously treated brain metastases may participate provided they are
stable (e.g., without evidence of progression by radiographic imaging for at
Uncontrolled angina within the 3 months prior to consent
least 28 days before the first dose of study treatment and neurologic symptoms
Any history of clinically significant arrhythmias (such as ventricular tachycardia, ventricular fibrillation, torsades de pointes, or poorly controlled atrial fibrillation)
Corrected QT (QTc) prolongation > 480 msec
have returned to baseline), and have no evidence of new or enlarging brain
History of other clinically significant cardiovascular disease (i.e., cardiomyopathy, congestive heart failure with New York Heart Association [NYHA] functional classification III-IV, pericarditis, significant pericardial effusion, significant coronary stent occlusion, poorly controlled deep venous thrombosis, etc)
metastases or central nervous system (CNS) edema, and does not require
Cardiovascular disease-related requirement for daily supplemental oxygen
steroids at least 7 days before the first dose of study treatment
History of two or more myocardial infarctions OR two or more coronary revascularization procedures
Subjects with history of myocarditis, regardless of etiology
History of thromboembolic or cerebrovascular events =< 12 weeks prior to the first dose of study treatment. Examples include transient ischemic attacks, cerebrovascular accidents, hemodynamically significant (i.e. massive or sub-massive) deep vein thrombosis or pulmonary emboli
Note: Patients with either deep vein thrombosis or pulmonary emboli that does not result in hemodynamic instability are allowed to enroll as long as they are on a stable dose of anticoagulants for at least 4 weeks
Note: Patients with thromboembolic events related to indwelling catheters or other procedures may be enrolled
Participants with a condition requiring systemic treatment with corticosteroids (> 10 mg daily prednisone or equivalent)
Subjects receiving any other investigational or standard antineoplastic agents
Patients with severe grade 3-4 toxicities due to anti-PD-1 monotherapy during first line. Toxicities due to combination PD-1/CTLA-4 blockade will not be exclusionary
Inability to give informed consent
History of malignancies except cured basal cell carcinoma, cutaneous squamous cell carcinoma, melanoma in situ, superficial bladder cancer or carcinoma in situ of the cervix; for other malignancies, must be documented to be free of cancer for >= 2 years. All other cases can be considered on a case by case basis at the discretion of the principal investigator
Any condition that might interfere with the subject's participation in the study, safety, or in the evaluation of the study results
Concurrent enrollment in another clinical study, unless it is an observational (non-interventional) clinical study or the follow-up period of an interventional study
A confirmed history of encephalitis, meningitis, or uncontrolled seizures in the year
Active or prior documented inflammatory bowel disease
prior to informed consent
History of (non-infectious) interstitial lung disease (ILD)/pneumonitis that required steroids or has current ILD/pneumonitis or where suspected ILD/pneumonitis cannot be ruled out by imaging at screening
Impairment of gastrointestinal function or disease which may significantly alter the absorption of study drug (e.g., active ulcerative disease, uncontrolled vomiting or diarrhea, malabsorption syndrome, small bowel resection with decreased intestinal absorption), or recent (=< 3 months) history of a partial or complete bowel obstruction, or other conditions that will interfere significantly with the absorption of oral drugs
Concurrent neuromuscular disorder that is associated with elevated creatine kinase (CK) (e.g., inflammatory myopathies, muscular dystrophy, amyotrophic lateral sclerosis, spinal muscular atrophy)
History or current evidence of retinal venous occlusion (RVO) or current risk factors for RVO (e.g., uncontrolled glaucoma or ocular hypertension, history of hyperviscosity or hypercoagulability syndromes); history of retinal degenerative disease
Prisoners or subjects who are involuntarily incarcerated
Note: under certain specific circumstances a person who has been imprisoned may be included or permitted to continue as a subject
Subjects who are compulsorily detained for treatment of either a psychiatric or physical (e.g., infectious disease) illness
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note